CYP3A5 and ABCB1 genes and hypertension

Pharmacogenomics

Volumn 10, Issue 3, 2009, Pages 477-487

  Bochud, Murielle ^a   Bovet, Pascal ^a   Burnier, Michel ^b   Eap, Chin B ^c,d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

ABCB1; Blood pressure; CYP3A5; Dietary salt intake; Gene gene interaction; Hypertension; Renin angiotensin system

Indexed keywords

ADENINE; ALANINE; ALDOSTERONE; ANGIOTENSIN II; CYCLOSPORIN; CYTOCHROME P450 3A5; CYTOSINE; GUANINE; MULTIDRUG RESISTANCE PROTEIN 1; SERINE; SODIUM; SPIRONOLACTONE; THYMINE; ABCB1 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; GLYCOPROTEIN P; MESSENGER RNA;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BLOOD PRESSURE REGULATION; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE INTERACTION; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HORMONE TRANSPORT; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SODIUM EXCRETION; ZYGOSITY; ALTERNATIVE RNA SPLICING; BLOOD PRESSURE; ENZYMOLOGY; FEMALE; GENETICS; HOMEOSTASIS; INTRON; MALE; METABOLISM; PHYSIOLOGY;

RATTUS;

ALTERNATIVE SPLICING; BLOOD PRESSURE; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; HOMEOSTASIS; HUMANS; HYPERTENSION; INTRONS; MALE; P-GLYCOPROTEIN; RNA, MESSENGER;

EID: 65649114292     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.3.477     Document Type: Review

References (98)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001, systematic analysis of population health data. Lancet 367, 1747-1757 (2006).
2. Wolf-Maier K, Cooper RS, Banegas JR et al.: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289, 2363-2369 (2003).
3. Firmann M, Mayor V, Marques-Vidal PM et al.: The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc. Disord. 8, 6 (2008).
4. Brown MJ: Hypertension and ethnic group. BMJ 332, 833-836 (2006).
5. Bovet P, Shamlaye C, Gabriel A, Riesen W, Paccaud F: Prevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy. BMC Public Health 6, 9 (2006).
6. Kannel WB, Wolf PA, Verter J, McNamara PM: Epidemiologic assessment of the role of blood pressure in stroke: the Framingham Study. 1970 [see comments]. JAMA 276, 1269-1278 (1996).
7. van der Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D: The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N. Engl. J. Med. 342, 1-8 (2000).
8. Flack JM, Neaton J, Grimm RJ et al.: Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 92, 2437-2445 (1995).
9. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL: The progression from hypertension to congestive heart failure. JAMA 275, 1557-1562 (1996).
10. Klag MJ, Whelton PK, Randall BL et al.: Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 334, 13-18 (1996).
11. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S: Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41, 1341-1345 (2003).
12. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J: Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch. Intern. Med. 158, 2007-2014 (1998).
13. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F: High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation 116, 1488-1496 (2007).
14. Chiolero A, Bovet P, Paradis G, Paccaud F: Has blood pressure increased in children in response to the obesity epidemic? Pediatrics 119, 544-553 (2007).
15. Rotimi CN, Cooper RS, Cao G et al.: Maximum-likelihood generalized heritability estimate for blood pressure in Nigerian family. Hypertension 33, 874-878 (1999).
16. Abney C, McPeeks MS, Ober C: Broad and narrow heritabilities of quantitative traits in a founder population. Am. J. Hum. Genet. 68, 1302-1307 (2001).
17. Harrap SB, Stebbing M, Hopper JL, Hoang HN, Giles GG: Familial patterns of covariation for cardiovascular risk factors in adults. The Victorian Family Heart Study. Am. J. Epidemiol. 152, 704-715 (2000).
18. Kotchen TA, Kotchen JM, Grim CE et al.: Genetic determinants of hypertension: identification of candidate phenotypes. Hypertension 36, 7-13 (2000).
19. Levy D, DeStefano AL, Larson MG et al.: Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham Heart Study. Hypertension 36, 477-483 (2000).
20. Adeyemo AA, Omotade OO, Rotimi CN, Luke AH, Tayo BO, Cooper RS: Heritability of blood pressure in Nigerian families. J. Hypertens. 20, 859-863 (2002).
21. Gu C, Borecki IB, Gagnon J et al.: Familial resemblance for resting blood pressure with particular reference to racial differences: preliminary analyses from the HERITAGE Family Study. Hum. Biol. 70, 77-90 (1998).
22. Bochud M, Bovet P, Elston RC et al.: High heritability of ambulatory blood pressure in families of East African descent. Hypertension 45, 445-450 (2005).
23. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356, 1955-1964 (2000).
24. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353, 2008-2013 (1999).
25. Carretero OA, Oparil S: Essential hypertension. Part I: definition and etiology. Circulation 101, 329-335 (2000).
26. Harrap SB: Where are all the blood-pressure genes? Lancet 361, 2149-2151 (2003).
27. Moore JH, Williams SM: New strategies for identifying gene-gene interactions in hypertension. Ann. Med. 34, 88-95 (2002).
28. Monti J, Plehm R, Schulz H, Ganten D, Kreutz R, Hubner N: Interaction between blood pressure quantitative trait loci in rats in which trait variation at chromosome 1 is conditional upon a specific allele at chromosome 10. Hum. Mol. Genet. 12, 435-439 (2003).
29. Sugiyama F, Churchill GA, Higgins DC et al.: Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. Genomics 71, 70-77 (2001).
30. Dutil J, Eliopoulos V, Tremblay J, Hamet P, Charron S, Deng AY: Multiple quantitative trait loci for blood pressure interacting epistatically and additively on Dahl rat chromosome 2. Hypertension 45, 557-564 (2005).
31. Palijan A, Lambert R, Dutil J, Sivo Z, Deng AY: Comprehensive congenic coverage revealing multiple blood pressure quantitative trait loci on Dahl rat chromosome 10. Hypertension 42, 515-522 (2003).
32. Kardia SL: Context-dependent genetic effects in hypertension. Curr. Hypertens. Rep. 2, 32-38 (2000).
33. Bochud M, Eap CB, Elston RC et al.: Association of CYP3A5 genotypes with blood pressure and renal function in African families. J. Hypertens. 24, 923-929 (2006).
34. Kuznetsova T, Staessen JA, Brand E et al.: Sodium excretion as a modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension. J. Hypertens. 24, 235-242 (2006).
35. De Wardener HE, McGregor GA: The natriuretic hormone and essential hypertension. Lancet 1, 1450-1454 (1982).
36. Lifton RP: Molecular genetics of human blood pressure variation. Science 272, 676-680 (1996).
37. Meneton P: Comparative roles of the renal apical sodium transport systems in blood pressure control. J. Am. Soc. Nephrol. 11, S135-S139 (2000).
38. Bianchi G, Ferrari P, Staessen JA: Adducin polymorphism: detection and impact on hypertension and related disorders. Hypertension 45, 331-340 (2005).
39. Tikhonoff V, Kuznetsova T, Stolarz K et al.: β-adducin polymorphisms, blood pressure, and sodium excretion in three European populations. Am. J. Hypertens. 16, 840-846 (2003).
40. Hunt SC, Cook NRC, Oberman A et al.: Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension trials of hypertension prevention, Phase II. Hypertension 32, 393-401 (1998).
41. Hunt SC, Geleijnse JM, Wu LL, Witteman JC, Williams RR, Grobbee DE: Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. Am. J. Hypertens. 12, 460-466 (1999).
42. Eap CB, Bochud M, Elston RC et al.: The CYP3A5 and ABCB1 genes encoding drug-and hormone-metabolizing and transporting proteins influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension 49, 1007-1014 (2007).
43. Kurzawski M, Pawlik A, Gornik W, Drozdzik M: Frequency of common MDR1 gene variants in a Polish population. Pharmacol. Rep. 58, 35-40 (2006).
44. Ameyaw MM, Regateiro F, Li T et al.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11, 217-221 (2001).
45. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Mulddrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics 15, 693-704 (2005).
46. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315, 525-528 (2007).
47. Siegsmund M, Brinkmann U, Schaffeler E et al.: Association of the P-glycoprotein transporter MDR1 (C34357) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 13, 1847-1854 (2002).
48. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478 (2000).
49. Owen A, Chandler B, Bray PG et al.: Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J. Virol. 78, 12022-12029 (2004).
50. Fellay J, Marzolini C, Meaden ER et al.: Response to antiretroviral treatment in HIV-1-infectcd individuals with allelic variants of the multidrug resistance transporter 1, a pharmacogenetics study. Lancet 359, 30-36 (2002).
51. Hauser IA, Koziolek M, Hopfer U, Thevenod F: Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int. 54, 1139-1149 (1998).
52. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 84, 7735-7738 (1987).
53. Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN: Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 77, 284-289 (1997).
54. Sugawara I, Hamada H, Nakahama M, Okamoto S, Tsuruo T, Mori S: Further characterization of the human adrenal-derived P-glycoprotein recognized by monoclonal antibody MRK 16 reacting with only human P-glycoprotein. Jpn J. Cancer Res. 80, 1199-1205 (1989).
55. Uhr M, Holsboer F, Muller MB: Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both MDR1A and MDR1B P-glycoproteins. J. Neuroendocrinol. 14, 753-759 (2002).
56. Ueda K, Okamura N, Hirai M et al.: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267, 24248-24252 (1992).
57. Bello-Reuss E, Ernest S, Holland OB, Hellmich MR: Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am. J. Physiol. Cell Physiol. 278, C1256-C1265 (2000).
58. Parker RB, Yates CR, Laizure SC, Weber KT: P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. J. Cardiovasc. Pharmacol. 47, 55-59 (2006).
59. Huang BS, Wang H, Leenen FHH: Chronic central infusion of aldosterone leads to sympathetic hyperreactivity and hypertension in Dahl S but not Dahl R rats. Am. J. Physiol. Heart Circ. Physiol. 288, H517-H524 (2005).
60. Huang BS, Cheung WJ, Wang H, Tan J, White RA, Leenen FH: Activation of brain renin-angiotensin-aldosterone system by central sodium in Wistar rats. Am. J. Physiol. Heart Circ. Physiol. 291, H1109-H1117 (2006).
61. Widder JD, Guzik TJ, Mueller CF et al.: Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 27, 762-768 (2007).
62. Zolk O, Jacobi J, Pahl A, Fromm MF, Schmieder RE: MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet. Genomics 17, 137-144 (2007).
63. Stern N, Lustig S, Petrasek D et al.: Cyclosporin A-induced hyperreninemic hypoaldosteronism. A model of adrenal resistance to angiotensin II. Hypertension 9, III31-III35 (1987).
64. Adu D, Turney J, Michael J, McMaster P: Hyperkalaemia in cyclosporin-treated renal allograft recipients. Lancet 2, 370-372 (1983).
65. Siest G, Jeannesson E, Visvikis-Siest S: Enzymes and pharmacogenetics of cardiovascular drugs. Clin. Chim. Acta 381, 26-31 (2007).
66. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP: Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin. Pharmacokinet. 47, 515-531 (2008).
67. Del Moral RG, Olmo A, Osuna A et al.: Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits. Transplant Proc. 30, 2014-2016 (1998).
68. Koziolek MJ, Riess R, Geiger H, Thevenod F, Hauser IA: Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int. 60, 156-166 (2001).
69. Foote CJ, Greer W, Kiberd BA et al.: MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients. Transplant Proc. 38, 2847-2849 (2006).
70. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG: Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab. Rev. 39, 699-721 (2007).
71. Daly AK: Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet. 45, 13-31 (2006).
72. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
73. Givens RC, Lin YS, Dowling AL et al.: CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J. Appl. Physiol. 95, 1297-1300 (2003).
74. Schuetz EG, Schuetz JD, Grogan WM et al.: Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch. Biochem. Biophys. 294, 206-214 (1992).
75. Roberts PJ, Rollins KD, Kashuba AD et al.: The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab. Dispos. 36, 1465-1469 (2008).
76. Ho H, Pinto A, Hall SD et al.: Association between the CYP3A5 genotype and blood pressure. Hypertension 45, 1-5 (2005).
77. Chowbay B, Zhou S, Lee EJ: An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab. Rev. 37, 327-378 (2005).
78. Ghosh SS, Basu AK, Ghosh S et al.: Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. Biochem. Pharmacol. 50, 49-54 (1995).
79. Watlington CO, Kramer LB, Schuetz EG et al.: Corticosterone 6 β-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am. J. Physiol. 262, F927-F931 (1992).
80. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di RA: CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75, 1059-1069 (2004).
81. Pemberton TJ, Mehra NU, Witonsky D et al.: Prevalence of common disease-associated variants in Asian Indians. BMC Genet. 9, 13 (2008).
82. Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE: CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet. Genomics 15, 737-741 (2005).
83. Kreutz R, Zuurman M, Kain S, Bolbrinker J, de Jong PE, Navis G: The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet. Genomics 15, 831-837 (2005).
84. Kivisto KT, Niemi M, Schaeffeler E et al.: CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE study. Am. J. Pharmacogenomics 5, 191-195 (2005).
85. Langaee TY, Gong Y, Yarandi HN et al.: Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin. Pharmacol. Ther. 81, 386-391 (2007).
86. Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J: The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14, 665-671 (2004).
87. Lieb W, Bolbrinker J, Doring A et al.: No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy. Clin. Sci. (Lond). 111, 365-372 (2006).
88. Warrington JS, Greenblatt DJ, von Moltke LL: Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. J. Pharmacol. Exp. Ther. 309, 720-729 (2004).
89. Jin Y, Wang YH, Miao J et al.: Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin. Pharmacol. Ther. 82, 579-585 (2007).
90. Kamdem LK, Hamilton L, Cheng C et al.: Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet. Genomics 18, 507-514 (2008).
91. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P450 5A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49, 311-318 (1996).
92. Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M: A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol. Chem. 386, 503-513 (2005).
93. Burk O, Koch I, Raucy J et al.: The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol. Chem. 279, 38379-38385 (2004).
94. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276, 14581-14587 (2001).
95. Lamba J, Strom S, Venkataramanan R et al.: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther. 79, 325-338 (2006).
96. Hamlyn JM, Hamilton BP, Manunta P: Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis. J. Hypertens. 14, 151-167 (1996).
97. Brouillard F, Tondelier D, Edelman A, Baudouin-Legros M: Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. Cancer Res. 61, 1693-1698 (2001).
98. Rautio J, Humphreys JE, Webster LO et al.: In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab. Dispos. 34, 786-792 (2006).